IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.
A Look At IQVIA Holdings (IQV) Valuation After Charles River Deal And Fresh Analyst Coverage
IQVIA Holdings (IQV) is gaining investor attention following a planned acquisition of Charles River Laboratories’ discovery services assets and new analyst coverage. Despite recent positive share price movements, longer-term returns have been weaker. The company is currently considered 31.4% undervalued, with a narrative fair value of $250.00, driven by a record R&D Solutions backlog and strong demand for outsourced clinical research, particularly in specialized therapeutic areas.